As GLP-1 medications gain popularity for weight loss, many users face the dilemma of whether they can stop the injections without regaining weight. Experts highlight the risks associated with discontinuation and emphasize the need for a solid maintenance plan to sustain health i…
As metabolic health gains prominence in wellness discussions, the roles of NAD+ and GLP-1 therapies are increasingly scrutinized. This article clarifies how GLP-1 medications like…
Eli Lilly has reported a significant revenue increase of 47% in the second quarter, reaching $22.97 billion, despite a decline in employer insurance coverage for GLP-1 weight-loss…
The FDA has approved Eli Lilly's medication Mounjaro for reducing the risk of heart events in individuals with Type 2 diabetes. This approval adds to the drug's existing use for b…
This article examines the potential of GLP-1 receptor agonists, commonly used for type 2 diabetes and obesity, in treating polyendocrine metabolic ovarian syndrome (PMOS). Experts…
The Medicare GLP-1 Bridge program offers eligible beneficiaries access to weight loss drugs at a reduced cost of $50 per month. However, patients with certain medical conditions,…
Researchers at UC Berkeley have discovered that the compound TOFA can enhance energy expenditure and reduce body fat without causing muscle loss in mice. This approach contrasts w…
Recent data indicates a potential decline in obesity rates in the United States, marking a significant shift in a longstanding public health issue. This change coincides with the…
As obesity medications evolve, researchers are exploring new hormone combinations to enhance treatment effectiveness and tolerability. Current studies focus on therapies that not…
The death of 19-year-old Josephine Nasr, a law student in London, has sparked serious concerns regarding the safety of tirzepatide, a GLP-1 weight loss drug. Following her prescri…
A recent study published in the Journal of the American Medical Association forecasts that nearly half of U.S. adults will have obesity by 2035, highlighting significant dispariti…
Older adults taking GLP-1 medications such as Ozempic and Wegovy should focus on adequate protein, calcium, and vitamin D intake to maintain muscle and bone health during weight l…
NVIDIA and Eli Lilly have both reported impressive quarterly earnings, showcasing their respective growth potential. NVIDIA's revenue surged by over 105% year-over-year, driven by…